AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+14.73%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$676M
AUM Growth
+$676M
(+5.9%)
Cap. Flow
-$4.11M
Cap. Flow
% of AUM
-0.61%
Top 10 Holdings %
Top 10 Hldgs %
50.78%
Holding
109
New
10
Increased
19
Reduced
24
Closed
14
Top Buys
| 1 |
Insmed
INSM
|
$33.7M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$32M |
| 3 |
Ventyx Biosciences
VTYX
|
$9.71M |
| 4 |
Lexeo Therapeutics
LXEO
|
$8.48M |
| 5 |
Enliven Therapeutics
ELVN
|
$8.02M |
Top Sells
| 1 |
Apogee Therapeutics
APGE
|
$19.9M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$16.8M |
| 3 |
Merus
MRUS
|
$13.3M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$8.5M |
| 5 |
INZY
Inozyme Pharma
INZY
|
$8.47M |
Sector Composition
| 1 | Healthcare | 95.02% |
| 2 | Financials | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Akebia Therapeutics
AKBA
$827M
| $7.1M | 0.97% |
1,950,000
+450,000
| +30% | +$1.64M |
|
|
INZY
27
DELISTED
Inozyme Pharma
INZY
| $7M | 0.96% |
1,749,359
-2,118,351
| -55% | -$8.47M |
|
|
AUTL
28
Autolus Therapeutics
AUTL
$383M
| $6.94M | 0.95% |
3,045,000
| – | – |
|
|
ORKA
29
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $6.77M | 0.92% |
603,479
+58,117
| +11% | +$651K |
|
30
BridgeBio Pharma
BBIO
$9.91B
| $6.48M | 0.88% |
150,000
-150,000
| -50% | -$6.48M |
|
31
Viridian Therapeutics
VRDN
$1.59B
| $5.45M | 0.74% |
390,000
| – | – |
|
32
Axsome Therapeutics
AXSM
$6.09B
| $5.22M | 0.71% |
50,000
-50,000
| -50% | -$5.22M |
|
33
Erasca
ERAS
$406M
| $5.19M | 0.71% |
4,085,787
+744,268
| +22% | +$945K |
|
34
NewAmsterdam Pharma
NAMS
$2.8B
| $4.98M | 0.68% |
275,000
-50,000
| -15% | -$906K |
|
|
CBIO
35
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $4.52M | 0.62% |
+280,031
| New | +$4.52M |
|
36
Roivant Sciences
ROIV
$8.6B
| $4.51M | 0.62% |
400,000
+250,000
| +167% | +$2.82M |
|
37
Crinetics Pharmaceuticals
CRNX
$3.26B
| $4.38M | 0.6% |
152,252
| – | – |
|
38
Vaxcyte
PCVX
$4.17B
| $4.06M | 0.56% |
125,000
+100,000
| +400% | +$3.25M |
|
|
PCSC
39
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $3.71M | 0.51% |
350,000
| – | – |
|
|
40
Merus
MRUS
$5.04B
| $3.68M | 0.5% |
70,000
-251,962
| -78% | -$13.3M |
|
41
Perspective Therapeutics
CATX
$251M
| $3.61M | 0.49% |
1,050,000
-1,174,196
| -53% | -$4.04M |
|
42
Avalo Therapeutics
AVTX
$139M
| $3.03M | 0.41% |
607,872
-49,282
| -7% | -$246K |
|
|
OACCU
43
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
$191M
| $2.66M | 0.36% |
250,000
| – | – |
|
44
Jazz Pharmaceuticals
JAZZ
$7.99B
| $2.65M | 0.36% |
+25,000
| New | +$2.65M |
|
45
Monopar Therapeutics
MNPR
$223M
| $2.42M | 0.33% |
67,500
+5,500
| +9% | +$197K |
|
|
RAPP
46
Rapport Therapeutics
RAPP
$549M
| $2.27M | 0.31% |
+199,643
| New | +$2.27M |
|
47
Geron
GERN
$893M
| $2.12M | 0.29% |
1,500,000
| – | – |
|
|
THRD
48
DELISTED
Third Harmonic Bio
THRD
| $2.01M | 0.27% |
370,000
| – | – |
|
49
Cullinan Oncology
CGEM
$456M
| $1.99M | 0.27% |
263,817
| – | – |
|
|
50
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $1.96M | 0.27% |
245,000
+3,043
| +1% | +$24.3K |
|